Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 25,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKROGet Free Report) CEO Andrew Cheng sold 25,000 shares of the business’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $49.77, for a total value of $1,244,250.00. Following the sale, the chief executive officer now owns 462,680 shares in the company, valued at $23,027,583.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Cheng also recently made the following trade(s):

  • On Monday, July 3rd, Andrew Cheng sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total transaction of $1,122,000.00.

Akero Therapeutics Stock Up 0.0 %

AKRO stock traded up $0.01 during midday trading on Monday, reaching $52.25. 1,240,847 shares of the company’s stock traded hands, compared to its average volume of 673,458. Akero Therapeutics, Inc. has a 52 week low of $25.21 and a 52 week high of $58.38. The company has a market cap of $2.91 billion, a price-to-earnings ratio of -20.41 and a beta of -0.94. The firm’s fifty day moving average price is $46.43 and its 200-day moving average price is $45.30. The company has a quick ratio of 29.78, a current ratio of 29.77 and a debt-to-equity ratio of 0.04.

Akero Therapeutics (NASDAQ:AKROGet Free Report) last issued its quarterly earnings data on Friday, August 11th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.01. As a group, sell-side analysts forecast that Akero Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Hong Kong Ltd bought a new stake in shares of Akero Therapeutics in the 1st quarter worth $32,000. Osaic Holdings Inc. boosted its holdings in Akero Therapeutics by 24.8% during the second quarter. Osaic Holdings Inc. now owns 1,809 shares of the company’s stock worth $84,000 after purchasing an additional 359 shares during the last quarter. Royal Bank of Canada grew its position in Akero Therapeutics by 9.9% in the 3rd quarter. Royal Bank of Canada now owns 2,605 shares of the company’s stock worth $89,000 after purchasing an additional 235 shares in the last quarter. Quantbot Technologies LP increased its stake in Akero Therapeutics by 616.8% in the 2nd quarter. Quantbot Technologies LP now owns 10,100 shares of the company’s stock valued at $95,000 after buying an additional 8,691 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Akero Therapeutics by 104.5% during the 4th quarter. Wells Fargo & Company MN now owns 1,817 shares of the company’s stock worth $100,000 after buying an additional 42,582 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have recently weighed in on AKRO. JPMorgan Chase & Co. increased their price target on Akero Therapeutics from $49.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, September 5th. HC Wainwright increased their price objective on shares of Akero Therapeutics from $62.00 to $64.00 in a research report on Wednesday, June 7th. Evercore ISI boosted their target price on shares of Akero Therapeutics from $50.00 to $60.00 and gave the company an “outperform” rating in a report on Wednesday, September 13th. Finally, UBS Group initiated coverage on Akero Therapeutics in a report on Monday, August 28th. They set a “buy” rating and a $83.00 price target for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $65.33.

Read Our Latest Research Report on Akero Therapeutics

About Akero Therapeutics

(Get Free Report)

Akero Therapeutics, Inc, a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.

See Also

Insider Buying and Selling by Quarter for Akero Therapeutics (NASDAQ:AKRO)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.